中国血液净化

中国血液净化 ›› 2022, Vol. 21 ›› Issue (10): 705-708.doi: 10.3969/j.issn.1671-4091.2022.10.001

• 一切为了人民健康--我们这十年·专题讲座 •    下一篇

伴有失代偿性心力衰竭慢性肾脏病的正性肌力药物的选择与应用

孙雪峰   

  1. 100853 北京，1解放军总医院第一医学中心肾脏病医学部、肾脏疾病国家重点实验室、慢性肾病国家临床医学研究中心 
  • 收稿日期:2022-06-28 修回日期:2022-07-06 出版日期:2022-10-12 发布日期:2022-10-12
  • 通讯作者: 孙雪峰 E-mail:xfssun@126.com
  • 基金资助:
    国家自然科学基金面上项目;国家自然科学基金面上项目

Application of inotropic agents in patients with chronic kidney disease accompanied by decompensated heart failure

SUN Xuefeng   

  1. Department of Nephrology, First Medical Center of Chinese PLA General Hospital; State Key Laboratory of Kidney Diseases; National Clinical Research Center for Kidney Diseases, Beijing 100853, China
  • Received:2022-06-28 Revised:2022-07-06 Online:2022-10-12 Published:2022-10-12
  • Contact: SUN Xuefeng E-mail:xfssun@126.com

PDF

62

摘要： 正性肌力药物是治疗失代偿性心力衰竭的常用药物，但慢性肾脏病患者如何选择与应用，缺乏指导性意见。本文在介绍不同种类正性肌力药物的药理作用基础上，基于循证证据评价正性肌力药物治疗伴有失代偿性心力衰竭的慢性肾脏病患者的获益与风险，旨在为临床医生合理应用正性肌力药物，提供借鉴和参考。

关键词: 正性肌力药物, 慢性肾脏病, 失代偿性心力衰竭

Abstract: Inotropic agents are commonly used in the treatment of decompensated heart failure, but there is still no guidance on how to choose and apply them in patients with chronic kidney disease (CKD). Based on evidence-based medicine, this paper introduces the pharmacological effects of different kinds of inotropic agents and evaluated the benefits and risks of them in the treatment decompensated heart failure in CKD patients. This papers aim is to provide reference for clinicians in rational application of inotropic agents. 

Key words:  Inotropic agents, Chronic kidney disease, Decompensated heart failure

中图分类号: